Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Squamous cell carcinoma of the head and neck
0.030 Biomarker disease BEFREE Anti-programmed death-1 (PD-1) receptor-based therapeutics improve survival in patients with recurrent head and neck squamous cell carcinoma (HNSCC), but many do not benefit due to a low response rate. 31562203 2020
Squamous cell carcinoma of the head and neck
0.030 Biomarker disease BEFREE Immune therapies, in particular those targeting the PD1 receptor or its ligand PD-L1, including nivolumab, pembrolizumab, durvalumab, and atezolizumab have shown significant efficacy in subsets of patients with HNSCC. 29355614 2018
Squamous cell carcinoma of the head and neck
0.030 AlteredExpression disease BEFREE Pembrolizumab is an anti-programmed death 1 (PD-1) receptor monoclonal antibody that has shown activity as second line treatment for metastatic head and neck squamous cell carcinoma (HNSCC). 29548299 2018